{"schema_version":"secwatch.filing_event.v1","accession":"0001798749-23-000059","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.500886+00:00","generated_at":"2026-06-08T05:20:45.106397+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aerovate Therapeutics reports Q3 2023 net loss of $19.6M; Phase 2b/3 trial on track for Q2 2024 data","bullets":["Net loss of $19.6M for Q3 2023, compared to $13.6M in Q3 2022; includes $3.2M stock-based compensation.","R&D expenses rose to $16.9M from $10.8M YoY, driven by higher clinical trial and headcount costs.","Cash, equivalents and securities totaled $135.2M at September 30, 2023, sufficient to fund operations into 2026.","IMPAHCT Phase 2b/3 trial of AV-101 for PAH expects topline Phase 2b data in Q2 2024; over 125 sites active globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001798749-23-000059","json":"https://secwatch.observer/filing/0001798749-23-000059.json","markdown":"https://secwatch.observer/filing/0001798749-23-000059.md","text":"https://secwatch.observer/filing/0001798749-23-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000059/0001798749-23-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000059/tmb-20231113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:20:45.106397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"838d7ed4e0a421ae1ba16192dd92968df5c800c3","claim":"Jade Biosciences, Inc. reported the quarter ended September 30, 2023 results: net income $19.6 million.","evidence_excerpt":"Aerovate Therapeutics, Inc. announced its third quarter financial results and business highlights for the period ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000059/0001798749-23-000059-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"$19.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}